-
9002480-10
Cannabinol monomethyl ether-10 mg
Price: $1,160.31List Price: $1,289.23A phytocannabinoid whose physiological and toxicological properties are not known -
9002480-5
Cannabinol monomethyl ether-5 mg
Price: $653.59List Price: $726.22A phytocannabinoid whose physiological and toxicological properties are not known -
25495-50
Cannabinol-50 mg UN1230 PG II
Price: $616.88List Price: $685.43An analytical reference standard categorized as a phytocannabinoid intended for research and forensic applications -
-
-
S417130-1G
CYCLOHEXYL DICYCLOPROPYL CARBINOL
Price: $91.69List Price: $101.88CYCLOHEXYL DICYCLOPROPYL CARBINOL -
90235-50
Dihomo-y-Linolenoyl Ethanolamide-50 mg
Price: $1,104.09List Price: $1,226.77An endocannabinoid containing dihomo-&gamma-linoleate in place of the arachidonate moiety of AEA binds to recombinant human CB1 and CB2 receptors with Ki values of 857 and 598 nM, respectively. -
SML2732-5MG
DO34 (C005B-310197)
Price: $283.96List Price: $315.51Biochem/physiol Actions DO34 is a brain-penetrant, selective and highly potent diacylglycerol lipase inhibitor (recom human DAGLα:/β: pIC 50 = 8.2/8. -
SML2732-25MG
DO34 (C005B-310198)
Price: $914.97List Price: $1,016.63Biochem/physiol Actions DO34 is a brain-penetrant, selective and highly potent diacylglycerol lipase inhibitor (recom human DAGLα:/β: pIC 50 = 8.2/8. -
H7909-5MG
HU-210 -- DEA SCHEDULE I ITEM
Price: $3,992.01List Price: $4,435.56Biochem/physiol Actions Cannabinoid receptor agonist. Features and Benefits This compound is featured on the Cannabinoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. -
J646666-100mg
JNJ-42226314 (C007B-362894)
Price: $2,864.69List Price: $3,182.99JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy -
J646666-10mg
JNJ-42226314 (C007B-362895)
Price: $706.50List Price: $785.00JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy